Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Ohio State University
•
NCI-CCC GI Tumor Board Question
Do you recommend checkpoint inhibitors after concurrent chemoradiation for GEJ adenocarcinoma patients who are not surgical candidates?
If you do offer immunotherapy, how long would you recommend the treatment?
Related Questions
Would you recommend adjuvant chemotherapy for a patient who achieved a CR after TNT for stage III rectal adenocarcinoma but underwent no initial surgery, and now has a local recurrence >12 months later with plans to undergo low-anterior resection?
In patients with HCC and asymptomatic but endoscopically visible varices, how long do you wait to start bevacizumab after banding?
How do you approach neoadjuvant/adjuvant therapy in MSI-H locally advanced gastric cancer without an opportunity to enroll in a clinical trial?
How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?
How would you approach adjuvant therapy for a patient with resected T4N1 high grade large cell neuroendocrine tumor of the cecum with adenocarcinoma component?
How would you approach a patient with newly diagnosed hepatocellular carcinoma with very high AFP (>100,000) but no clear radiographic evidence of metastatic disease?
Would you consider hormone replacement therapy in young women with germline BRCA1 mutation and history of triple negative breast cancer who underwent bilateral mastectomy and prophylactic bilateral salpingo-oophorectomy?
For a young patient who had a prior pCR to neoadjuvant therapy, would you consider systemic therapy after local resection and radiation of an isolated brain metastatic recurrence of triple negative breast cancer?
Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?
When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?